Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2237135 | 0.85 | MEN1 (0.44) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL3956281 | 0.82 | TDP1 (0.49) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL21728958 | 0.79 | TDP1 (0.63) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL1785910 | 0.79 | TDP1 (0.49) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL15728746 | 0.78 | CTSK (0.50) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL25827367 | 0.78 | GAA (0.58) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL8025174 | 0.78 | TDP1 (0.45) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL1784924 | 0.77 | CTSK (0.51) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL156233 | 0.76 | TDP1 (0.46) | TDP1MEN1KMT2AGAACA1 | |
| SCHEMBL15775938 | 0.76 | KDM4E (0.40) | TDP1MEN1KMT2AGAACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9790219-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3116501-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| WO-2016105477-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLTHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105477-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLTHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015138909-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392378-B2 | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, ABCC5, ABCB1 | TDP1 3575/4885MEN1 4884/4885KMT2A 3408/4885 |
| US-20170369482-A1 | DERIVATIVES OF 5-PHENYL- OR 5-HETEROARYLATHIAZOL-2-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, ABCC5, ABCB1 | TDP1 3575/4885MEN1 4884/4885KMT2A 3408/4885 |
| US-20170001993-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, KEAP1 | TDP1 2671/4885MEN1 3688/4885KMT2A 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.